MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, announced its upcoming investor awareness initiatives today. In addition, the company will be conducting a presentation today at the Future of Food Investment Conference; one-on-one investor meetings are also being scheduled for next week. According to the announcement, MustGrow’s key programs and catalysts include testing of its biopesticide, which is formulated to stop Fusarium wilt TR4, a disease pathogen ravaging the $25 billion global banana industry; filing of key patents and progress on proof-of-concept data related to a biological weed killer; and confirmation of more than 98% control of Clubrootspores in soil and on plants achieved in a 24-hour time frame. The announcement noted that, as synthetic chemicals continue to be banned or deregistered globally, the time for biopesticides as arrived. The U.S. Environmental Protection Agency supports the use of safer pesticides, and the European Commission has announced a goal to cut in half the use of chemical pesticides by 2030. In addition, there has been a surging interest in biopesticide and bioherbicide crop protection from agriculture companies, with one study projecting that the global biopesticide market size will double to $8.5 billion by 2025. MustGrow’s Future of Food Investment Conference presentation is scheduled for today (Nov. 24) at 1:50 p.m. ET.
To view the full presentation, visit https://ibn.fm/XvBwj
To view the full press release, visit https://ibn.fm/DKCAH
About MustGrow Biologics Corp
MustGrow is a publicly traded agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits & vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit & vegetables. MustGrow has now concentrated a liquid format, TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. The company has approximately 37 million basic common shares issued and outstanding. For further details, please visit www.MustGrow.ca.
NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork